This series re-examines the concurrent controversies at the Cancer Prevention and Research Institute of Texas and MD Anderson Cancer Center. This examination is possible in part because of new insight provided by Alfred Gilman, a Nobel laureate who served as the first scientific director of the state institution that distributes $300 million a year. Gilman died on Dec. 23, 2015.
THE OVARIAN CANCER NATIONAL ALLIANCE and the OVARIAN CANCER RESEARCH FUND announced a merger, forming the Ovarian Cancer Research Fund Alliance. The new body will be the largest global organization dedicated to advancing ovarian cancer research.
TARA YATES was named director of communications of the Wistar Institute.
FDA approved Zepatier (elbasvir and grazoprevir) for the treatment of adult patients with chronic hepatitis C virus genotype 1 or 4 infection, with or without ribavirin, following priority review.
FDA approved Halaven (eribulin mesylate) Injection for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen, following priority review.
JUDY KEEN was named director of scientific affairs of the American Society for Radiation Oncology.
CARMEN SOLÓRZANO was named chief of the Division of Surgical Oncology and Endocrine Surgery at Vanderbilt University Medical Center. Solórzano is a professor of Surgery and director of the Endocrine Surgery Center.
FDA granted accelerated approval to a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.
MINESH MEHTA joined Miami Cancer Institute at Baptist Health South Florida as deputy director and chief of radiation oncology.
In an unprecedented move, 69 NCI-designated cancer centers have come together to advocate for HPV vaccination as a preventive measure against many HPV-related cancers.
